$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil

$adil Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023024719 Filed on March 30, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.244M	$2.103M	$9.140M
YoY Change	-8.87%	0.17%	-2.19%
% of Gross Profit
Research & Development	$676.4K	$1.137M	$4.177M
YoY Change	13.43%	-51.27%	818.02%
% of Gross Profit
Depreciation & Amortization	$2.070K	$2.080K	$8.290K
YoY Change	0.0%	-48.26%	17.92%
% of Gross Profit
Operating Expenses	$2.921M	$3.240M	$13.32M
YoY Change	-4.52%	-26.91%	2826.84%
Operating Profit	-$2.921M		-$13.32M
YoY Change	-4.52%		-30.96%
Interest Expense	$28.89K	$47.82K	$63.21K
YoY Change	464.26%	2073.64%	866.51%
% of Operating Profit
Other Income/Expense, Net	$14.89K	$325.0K	$585.2K
YoY Change	-89.8%	501.74%	-321.41%
Pretax Income	-$2.906M	-$2.867M	-$12.73M
YoY Change	-0.07%	-51.61%	-34.77%
Income Tax		-$500.00	-$502.00
% Of Pretax Income
Net Earnings	-$2.906M	-$2.867M	-$12.73M
YoY Change	-0.07%	-50.84%	-34.45%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.11		-$0.51
Diluted Earnings Per Share	-$0.11	-$0.11	-$0.51
COMMON SHARES
Basic Shares Outstanding	28.52M shares	26.85M shares	25.04M shares
Diluted Shares Outstanding	26.46M shares		25.04M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.313M	$4.002M	$4.002M
YoY Change	-81.78%	-33.99%	-33.99%
Cash & Equivalents	$2.313M	$4.002M	$4.002M
Short-Term Investments
Other Short-Term Assets	$652.1K	$778.1K	$778.1K
YoY Change	136.4%	94.81%	94.81%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$2.965M	$4.780M	$4.780M
YoY Change	-77.13%	-26.03%	-26.03%
LONG-TERM ASSETS
Property, Plant & Equipment	$48.49K	$50.42K	$244.4K
YoY Change	-83.27%	-13.28%	-19.69%
Goodwill	$249.0K	$249.0K
YoY Change		0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$937.0K	$952.9K	$952.9K
YoY Change	-6.17%	-5.97%	-5.97%
TOTAL ASSETS
Total Short-Term Assets	$2.965M	$4.780M	$4.780M
Total Long-Term Assets	$937.0K	$952.9K	$952.9K
Total Assets	$3.902M	$5.733M	$5.733M
YoY Change	-72.06%	-23.31%	-23.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$530.1K	$393.8K	$393.8K
YoY Change	27.72%	37.61%	37.61%
Accrued Expenses	$1.184M	$1.155M	$1.387M
YoY Change	-32.18%	-51.42%	-42.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.798M	$1.791M	$1.791M
YoY Change	-17.19%	-34.22%	-34.22%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$641.1K	$642.6K	$642.6K
YoY Change	-39.63%	-47.39%	-47.39%
Total Long-Term Liabilities	$641.1K	$642.6K	$642.6K
YoY Change	-39.63%	-47.39%	-47.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.798M	$1.791M	$1.791M
Total Long-Term Liabilities	$641.1K	$642.6K	$642.6K
Total Liabilities	$2.462M	$2.456M	$2.456M
YoY Change	-24.4%	-38.08%	-38.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$66.58M	-$63.67M
YoY Change		24.99%
Common Stock	$28.52K	$26.69K
YoY Change		27.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.440M	$3.276M	$3.276M
YoY Change
Total Liabilities & Shareholders Equity	$3.902M	$5.733M	$5.733M
YoY Change	-72.06%	-23.31%	-23.31%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.906M	-$2.867M	-$12.73M
YoY Change	-0.07%	-50.84%	-34.45%
Depreciation, Depletion And Amortization	$2.070K	$2.080K	$8.290K
YoY Change	0.0%	-48.26%	17.92%
Cash From Operating Activities	-$2.299M	-$1.751M	-$11.19M
YoY Change	-7.93%	-26.22%	-6.39%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities		$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$9.124M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$609.6K	0.000	$9.126M
YoY Change	-93.32%	-100.0%	-33.12%
NET CHANGE
Cash From Operating Activities	-$2.299M	-1.751M	-$11.19M
Cash From Investing Activities		0.000
Cash From Financing Activities	$609.6K	0.000	$9.126M
Net Change In Cash	-$1.689M	-1.751M	-$2.060M
YoY Change		56.6%	-224.04%
FREE CASH FLOW
Cash From Operating Activities	-$2.299M	-$1.751M	-$11.19M
Capital Expenditures		$0.00
Free Cash Flow		-$1.751M	-$11.19M
YoY Change		-26.22%	-5.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Other Income OtherIncome		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38323
CY2022	dei	Entity Registrant Name EntityRegistrantName	ADIAL PHARMACEUTICALS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3074668
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1180 Seminole Trail
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 495
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Charlottesville
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22901
CY2022	dei	City Area Code CityAreaCode	(434)
CY2022	dei	Local Phone Number LocalPhoneNumber	422-9800
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2022	dei	Trading Symbol TradingSymbol	ADIL
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	31265353	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28516564	shares
CY2022	dei	Auditor Firm AuditorFirmId	711
CY2022	dei	Auditor Name AuditorName	Friedman LLP
CY2022	dei	Auditor Location AuditorLocation	Marlton, New Jersey
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4001794	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6062173	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	428700	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	9931	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	349441	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	389501	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4779935	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	6461605	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	50424	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	58149	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	4477	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5041	usd
CY2022Q4	adil	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	455000	usd
CY2021Q4	adil	Acquired Inprocess Research And Development AcquiredInprocessResearchAndDevelopment	455000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	193997	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	246209	usd
CY2022Q4	us-gaap	Goodwill Goodwill	248971	usd
CY2021Q4	us-gaap	Goodwill Goodwill	248971	usd
CY2022Q4	us-gaap	Assets Assets	5732804	usd
CY2021Q4	us-gaap	Assets Assets	7474975	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	393834	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	286192	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1154817	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2376930	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	175000	usd
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	56828	usd
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	49585	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	10387	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9683	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1790866	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2722390	usd
CY2022Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	492000	usd
CY2021Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	1014000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	150547	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	207375	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	22897	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	23399	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2456310	usd
CY2021Q4	us-gaap	Liabilities Liabilities	3967164	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26687295	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26687295	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20946712	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20946712	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	26687	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	20947	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66924338	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	54429979	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-63674531	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-50943115	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3276494	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3507811	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5732804	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7474975	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4176998	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8395648	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9140129	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9344678	usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1548397	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	13317127	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	19288723	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-13317127	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-19288723	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	63209	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	6539	usd
CY2022	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	522000	usd
CY2021	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-281713	usd
CY2021	us-gaap	Other Income OtherIncome	46494	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	585209	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-228680	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12731918	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19517403	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-502	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-94077	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12731416	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-19423326	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-353771	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11185985	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11949429	usd
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.04
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25037637	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18588748	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	3986066	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2259517	usd
CY2021	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	1980900	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	469501	usd
CY2021	adil	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	1424998	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	1060150	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	11750005	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-19423326	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3507811	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2101210	usd
CY2022	adil	Equitybased Compensation Stock Issuances To Consultants And Employees EquitybasedCompensationStockIssuancesToConsultantsAndEmployees	1273283	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	9123741	usd
CY2022	adil	Stock Issued During Period Value Warrant Exercised StockIssuedDuringPeriodValueWarrantExercised	1865	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12731416	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3276494	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-12731416	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-19423326	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3374493	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	4240417	usd
CY2021	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	29088	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	7725	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	6456	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-6954	usd
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1548397	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	564	usd
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	565	usd
CY2022	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	52212	usd
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	48085	usd
CY2022	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	522000	usd
CY2021	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-281713	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-502	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-94077	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	418769	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-223104	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-40060	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-112188	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1222113	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1520291	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	175000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-49585	usd
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-37337	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	108346	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64605	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-30589	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34016	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9123741	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11750005	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1865	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1424998	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	469501	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9125606	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13644504	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-2060379	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1661059	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6062173	usd
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4401114	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4001794	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6062173	usd
CY2021	adil	Reclassification Of Stockbased Comp From Accrued Expenses ReclassificationOfStockbasedCompFromAccruedExpenses	1060150	usd
CY2021	adil	Noncash Cost Of Commitment Shares NoncashCostOfCommitmentShares	732287	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">Significant items subject to such estimates and assumptions include the valuation of stock-based compensation, accruals associated with third party providers supporting clinical trials and pre-clinical activities, estimated fair values of long-lived assets used to assess the value of intangible assets, acquired in-process research and development (“IPR&D”), and goodwill, allocation of purchase price in business acquisitions, measurement of contingent liabilities, and income tax asset realization.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"> </p>
CY2022	adil	Warrants To Purchase Common Shares WarrantsToPurchaseCommonShares	12095870	shares
CY2021	adil	Warrants To Purchase Common Shares WarrantsToPurchaseCommonShares	7917982	shares
CY2022	adil	Common Shares Issuable On Exercise Of Options CommonSharesIssuableOnExerciseOfOptions	4316977	shares
CY2021	adil	Common Shares Issuable On Exercise Of Options CommonSharesIssuableOnExerciseOfOptions	3585310	shares
CY2022	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1083333	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17496180	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11503292	shares
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	3800000	usd
CY2022Q4	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.44	pure
CY2022	us-gaap	Servicing Asset At Fair Value Additions ServicingAssetAtFairValueAdditions	732287	usd
CY2022	adil	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included Other Comprehensive Income Loss FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedOtherComprehensiveIncomeLoss	-281713	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	1014000	usd
CY2022	adil	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Included Other Comprehensive Income FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainIncludedOtherComprehensiveIncome	522000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	492000	usd
CY2021Q1	adil	Owned Membership Interests OwnedMembershipInterests	0.2873	pure
CY2022	adil	Purchase Price Description PurchasePriceDescription	The purchase price of Purnovate consisted of cash consideration of $350,000 (excluding a $350,000 initial working capital loan to Purnovate, which was assumed by Adial at acquisition through its ownership of Purnovate, Purnovate’s liability and Adial’s asset being eliminated in consolidation), the issuance 699,980 shares of Adial common stock ($2.34 at date of closing, less a discount of 35% for a discount for lack of marketability related to the restrictions on the stock-based consideration) and contingent consideration for (i) certain development milestones in an aggregate amount of up to $2,100,000 for the first time any product or compound has achieved the relevant milestone within forty five (45) days after such occurrence (ii) milestones in an aggregate amount of up to $20,000,000 for each compound commercialized, and (iii) royalties of 3.0% of Net Sales (as defined in the Purchase Agreement). The equity consideration was placed into escrow to secure certain indemnification and other obligations of Purnovate and the Members and will be released, subject to certain terms.
CY2022	us-gaap	Acquisition Costs AcquisitionCosts	46000	usd
CY2022	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	350000	usd
CY2022	adil	Stock Consideration StockConsideration	1060150	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	732287	usd
CY2022	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	2142437	usd
CY2022	adil	Business Combination Research And Development Supplies BusinessCombinationResearchAndDevelopmentSupplies	-1548397	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	594040	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	380589	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	6954	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	294294	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	455000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets	1136837	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	910	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther	350000	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Capital Lease Obligation BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation	294294	usd
CY2022Q4	adil	Business Combination Paycheck Protection Program Loan BusinessCombinationPaycheckProtectionProgramLoan	29088	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	117476	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities	791768	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	345069	usd
CY2022Q4	us-gaap	Goodwill Goodwill	248971	usd
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	594040	usd
CY2021Q1	adil	Net Loss NetLoss	1923000	shares
CY2022Q4	us-gaap	Notes And Loans Payable NotesAndLoansPayable	29088	usd
CY2022Q4	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.01	pure
CY2022	adil	Paycheck Protection Program Term PaycheckProtectionProgramTerm	P2Y
CY2021Q2	us-gaap	Other Notes Payable OtherNotesPayable	29088	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	455000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	455000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	455000	usd
CY2022Q4	adil	Clinical Research Organization Services And Expenses ClinicalResearchOrganizationServicesAndExpenses	123386	usd
CY2021Q4	adil	Clinical Research Organization Services And Expenses ClinicalResearchOrganizationServicesAndExpenses	1826479	usd
CY2022Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	761509	usd
CY2021Q4	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	520795	usd
CY2022Q4	adil	Manufacturing Expenses ManufacturingExpenses	-197306	usd
CY2022Q4	adil	Legal And Consulting Services LegalAndConsultingServices	72616	usd
CY2021Q4	adil	Legal And Consulting Services LegalAndConsultingServices	29656	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1154817	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2376930	usd
CY2020Q4	adil	Membership Interest Description MembershipInterestDescription	Mr. Stilley owned approximately 28.7% of the membership interest of Purnovate and Mr. Newman controlled two entities that, together, own less than 1% of the membership interests of Purnovate. As a result of the foregoing, the Company formed a Special Committee of independent members of its Board of Directors to review and negotiate the acquisition terms.
CY2021Q1	adil	Securities Purchase Agreements Description SecuritiesPurchaseAgreementsDescription	the Company entered into Securities Purchase Agreements (the “SPAs”) with each of Bespoke, three entities controlled by James W. Newman, Jr., a member of the Company’s Board of Directors (“Newman”), and Keystone Capital Partners, LLC (“Keystone”), pursuant to which: (i) Bespoke agreed to purchase an aggregate of 336,667 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $1,010,001; (ii) Newman agreed to purchase an aggregate of 30,000 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $90,000; and (iii) Keystone agreed to purchase an aggregate of 333,334 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $1,000,002. In the year ended December 31, 2021, the Company issued 700,001 shares of common stock for total proceeds of $2,100,003. The shares sold pursuant to the SPAs were registered though a registration statement on Form S-3 that was filed with the SEC on April 20, 2021 and declared effective on May 26, 2021.
CY2021Q3	adil	Securities Purchase Agreements Description SecuritiesPurchaseAgreementsDescription	the Company entered into Securities Purchase Agreements, dated July 6, 2021 (the “SPAs”), with three pre-existing investors for an aggregate investment of $5,000,004 in consideration of the purchase by such investors of an aggregate of 1,666,667 shares of the Company’s common stock at a purchase price of $3.00 per share. SPAs were entered with each of Bespoke Growth Partners, Inc. (“Bespoke”), a company controlled by Mark Peikin, the Chief Strategy Officer of the Company at that time, Keystone Capital Partners, LLC (“Keystone”), and Richard Gilliam, a private investor (“Gilliam”) (collectively, the “Investors,” and each an “Investor”), pursuant to which: (i) Bespoke agreed to purchase an aggregate of 833,334 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $2,500,002; (ii) Keystone agreed to purchase an aggregate of 500,000 shares of the Company’s common stock at a purchase price of $3.00 per share for aggregate gross proceeds of $1,500,000; and (iii) Gilliam agreed to purchase an aggregate of 333,334 shares of the Company’s common stock at a purchase price of $3.00 per share for gross proceeds of $1,000,002.
CY2021Q4	adil	Shares Of Common Stock SharesOfCommonStock	200000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	150000	shares
CY2021Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2023-07-31
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	6.25
CY2021Q4	adil	Shares Of Common Stock SharesOfCommonStock	20000	shares
CY2021Q4	adil	Purchase An Additional Shares PurchaseAnAdditionalShares	180000	shares
CY2021Q4	adil	Sale Of Additional Shares SaleOfAdditionalShares	180000	shares
CY2021Q1	adil	Unregistered Share Of Common Stock UnregisteredShareOfCommonStock	669980	shares
CY2021Q1	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1060150	usd
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	10000	shares
CY2021Q1	adil	Exercise Price ExercisePrice	1.45
CY2021Q1	adil	Warrants Exercised WarrantsExercised	14500	usd
CY2021Q1	adil	Warrants For Purchase WarrantsForPurchase	712500	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2
CY2021Q1	adil	Warrants Exercised WarrantsExercised	1425000	usd
CY2022Q1	adil	Common Stock Issuances CommonStockIssuances	the Company, entered into a securities purchase agreement with an accredited institutional investor (“the Investor”) providing for the issuance of (i) 2,322,250 shares of the Company’s common stock, par value $0.001, (ii) pre-funded warrants to purchase up to 1,865,000 shares of common stock with an exercise price of $0.001 per share, which Pre-Funded Warrants are to be issued in lieu of shares of common stock to ensure that the Investor does not exceed certain beneficial ownership limitations, and (iii) warrants, with a term of five years and six months from the date of issuance, to purchase an aggregate of up to 3,977,888 shares of common stock at an exercise price of $2.52 per share.
CY2022Q1	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	9123741	usd
CY2022Q1	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	1865	usd
CY2022Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1865000	shares
CY2022	adil	Stock Issued During Period Shares Other1 StockIssuedDuringPeriodSharesOther1	470000	shares
CY2022	us-gaap	Dividends Common Stock Stock DividendsCommonStockStock	818350	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	During the year ended December 31, 2022, the Company issued employees 1,250,000 shares of common stock as bonuses, of which 1,083,333 remain outstanding. The first issuance of 250,000 shares were subject to forfeiture for nominal consideration to Company on termination of the employee, the shares no longer being liable to forfeiture (“vesting”) on the following schedule: 1/24 of 166,667 shares vesting on the date of issue and the first of each of the next twenty-three subsequent months, and 83,333 shares vesting on the third anniversary of the date of issue. On December 30, 2022, the 166,667 shares vesting over 24 months were canceled by the recipient at the recipient’s will, at which time the Company recognized the remaining $191,325 cost of the unvested shares cancelled. The second issuance of 1,000,000 shares are subject to forfeiture on the same conditions, but on the following schedule: 1/6 of the issued shares vesting six months from date of issue, then 1/12 vesting at the end of each subsequent three month period, the entire grant being vested three years from date of issue. On December 31, 2022, none of the uncancelled shares were vested and 1,083,333 shares remained subject to repurchase.
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	731667	shares
CY2022	adil	Weighted Averages Fair Value WeightedAveragesFairValue	1017095	usd
CY2022	adil	Weighted Average Fair Values Per Share WeightedAverageFairValuesPerShare	1.39
CY2022	adil	Unrecognized Compensation Expense UnrecognizedCompensationExpense	1939438	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y6M7D
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3374493	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4240417	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	8649625	shares
CY2021	adil	Weighted Average Remaining Term Outstanding Begining Balance WeightedAverageRemainingTermOutstandingBeginingBalance	P3Y5M15D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.6
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.02
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	53146	shares
CY2021	adil	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	2.26
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	712500	shares
CY2021	adil	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	2
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7990271	shares
CY2021	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y7M17D
CY2021Q4	adil	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercises Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice	4.82
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.14
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	6042888	shares
CY2022	adil	Weighted Average Exercise Price Issued WeightedAverageExercisePriceIssued	1.74
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	1865000	shares
CY2022	adil	Weighted Average Exercise Price Exercised WeightedAverageExercisePriceExercised	0.001
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	12168159	shares
CY2022	adil	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerms	P3Y14D
CY2022Q4	adil	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercises Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisesPrice	4.03
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue	0.01
CY2022	adil	Warrants To Purchase Shares Of Common Stock WarrantsToPurchaseSharesOfCommonStock	1865000	shares
CY2021	adil	Warrants To Purchase Shares Of Common Stock WarrantsToPurchaseSharesOfCommonStock	712500	shares
CY2022	adil	Total Proceeds TotalProceeds	1865	usd
CY2021	adil	Total Proceeds TotalProceeds	1424998	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0411	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.0243	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Assets EffectiveIncomeTaxRateReconciliationDispositionOfAssets	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Assets EffectiveIncomeTaxRateReconciliationDispositionOfAssets	-0.0167	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0051	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.006	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0402	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0278	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2142	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1861	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0048	pure
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-24473	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-24473	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	23971	usd
CY2022	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	23971	usd
CY2022	adil	Deferred Income Tax Expense Benefits DeferredIncomeTaxExpenseBenefits	-502	usd
CY2022	adil	Income Tax Expense Benefits IncomeTaxExpenseBenefits	-502	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	11378190	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9670286	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	171902	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	116147	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	52180	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	64623	usd
CY2022	us-gaap	Restricted Stock Expense RestrictedStockExpense	15982	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts	946624	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	12418870	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9692143	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	146008	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	158913	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-5221	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-1663	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	114871	usd
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	117340	usd
CY2022Q4	adil	Deferred Tax Assets Rou Assets DeferredTaxAssetsROUAssets	-48813	usd
CY2021Q4	adil	Deferred Tax Assets Rou Assets DeferredTaxAssetsROUAssets	63309	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	168905	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	182312	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	22897	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	23399	usd
CY2022	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	NOLS generated prior to 2018 will expire in 2037 and the 20- year carryover limitation was eliminated for losses generated after January 1, 2018, giving the taxpayer the ability to carry forward losses indefinitely. However, NOL carry forward arising after January 1, 2018, will now be limited to 80 percent of Taxable income.
CY2022Q4	adil	Deferred Tax Asset Valuation Allowance DeferredTaxAssetValuationAllowance	12400000	usd
CY2022Q2	adil	Effective Income Tax Rate Reconciliations At Federal Statutory Income Tax Rate Percent EffectiveIncomeTaxRateReconciliationsAtFederalStatutoryIncomeTaxRatePercent	0.01	pure
CY2022Q2	adil	Excise Tax Percentage ExciseTaxPercentage	0.01	pure
CY2022Q2	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1000000	usd
CY2022	adil	License Fees And Milestone Payments Description LicenseFeesAndMilestonePaymentsDescription	More specifically, the Company paid UVA LVG a license issue fee and is obligated to pay UVA LVG (i) annual minimum royalties of $40,000 commencing in 2017; (ii) a $20,000 milestone payments upon dosing the first patient under a Phase 3 human clinical trial of a licensed product, $155,000 upon the earlier of the completion of a Phase 3 trial of a licensed product, partnering of a licensed product, or sale of the Company, $275,000 upon acceptance of an NDA by the FDA, and $1,000,000 upon approval for sale of AD04 in the U.S., Europe or Japan; as well as (iii) royalties equal to a 2% and 1% of net sales of licensed products in countries in which a valid patent exists or does not exist, respectively, with royalties paid quarterly. In the event of a sublicense to a third party, the Company is obligated to pay royalties to UVA LVG equal to a percentage of what the Company would have been required to pay to UVA LVG had it sold the products under sublicense ourselves. In addition, the Company is required to pay to UVA LVG 15% of any sublicensing income.
CY2022	us-gaap	Royalty Expense RoyaltyExpense	40000	usd
CY2021	us-gaap	Royalty Expense RoyaltyExpense	40000	usd
CY2022Q2	adil	Accrued License Royalty Expense AccruedLicenseRoyaltyExpense	155000	usd
CY2022Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	40000	usd
CY2021Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	0	usd
CY2018Q4	adil	Master Services Agreement Description MasterServicesAgreementDescription	The MSA has a term of five years, automatically renewed for two-year periods, unless either party gives written notice of a decision not to renew the agreement six months prior to automatic renewal.
CY2018Q4	us-gaap	Exchange Fees ExchangeFees	3398957	usd
CY2018Q4	us-gaap	Exchange Fees ExchangeFees	3168895	eur
CY2022	adil	Exchange Rate ExchangeRate	1.0726
CY2022Q2	us-gaap	Payments For Fees PaymentsForFees	146765	usd
CY2022Q2	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	137375	usd
CY2022Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	454034	usd
CY2022Q2	us-gaap	Life Settlement Contracts Investment Method Carrying Amount LifeSettlementContractsInvestmentMethodCarryingAmount	410000	eur
CY2022	us-gaap	Other Noncash Income OtherNoncashIncome	209689	usd
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P4Y
CY2021Q1	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.09	pure
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	72828	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	75116	usd
CY2022	us-gaap	Lease Cost LeaseCost	72828	usd
CY2021	us-gaap	Lease Cost LeaseCost	75116	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	70202	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	67719	usd
CY2021	adil	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets	294294	usd
CY2022Q4	adil	Lease Right Of Use Assets LeaseRightOfUseAssets	193997	usd
CY2021Q4	adil	Lease Right Of Use Assets LeaseRightOfUseAssets	246209	usd
CY2022Q4	adil	Total Lease Assets TotalLeaseAssets	193997	usd
CY2021Q4	adil	Total Lease Assets TotalLeaseAssets	246209	usd
CY2022Q4	adil	Lease Liability Current Portion LeaseLiabilityCurrentPortion	56828	usd
CY2021Q4	adil	Lease Liability Current Portion LeaseLiabilityCurrentPortion	49585	usd
CY2022Q4	adil	Lease Liability Net Of Current Portion LeaseLiabilityNetOfCurrentPortion	150547	usd
CY2021Q4	adil	Lease Liability Net Of Current Portion LeaseLiabilityNetOfCurrentPortion	207375	usd
CY2022Q4	adil	Total Lease Liability TotalLeaseLiability	207375	usd
CY2021Q4	adil	Total Lease Liability TotalLeaseLiability	256960	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y29D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y29D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.09	pure
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Two LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo	72687	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Three LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree	75231	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due In Rolling Year Four LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour	77864	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	6508	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	232290	usd
CY2022Q4	adil	Operating Leases Future Minimum Payments Less Effects Of Discounting OperatingLeasesFutureMinimumPaymentsLessEffectsOfDiscounting	-24915	usd
CY2022Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	207375	usd
CY2022	us-gaap	Payments For Rent PaymentsForRent	1400	usd
CY2021	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	1400	usd
CY2022	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	416200	usd
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	375000	usd
CY2019Q3	us-gaap	Deferred Compensation Arrangement With Individual Distribution Paid DeferredCompensationArrangementWithIndividualDistributionPaid	300000	usd
CY2019Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.20	pure
CY2022Q4	us-gaap	Other Commitment OtherCommitment	209250	usd
CY2022	adil	Consulting Expenses ConsultingExpenses	151500	usd
CY2022	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	135000	usd
CY2022	us-gaap	Long Term Purchase Commitment Specified Form Of Payment LongTermPurchaseCommitmentSpecifiedFormOfPayment	$1,409,000
CY2022	adil	Advance Payment AdvancePayment	579000	usd
CY2022	us-gaap	Other Expenses OtherExpenses	398600	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	150300	usd
CY2022Q4	us-gaap	Cash Cash	64200	usd
CY2022Q4	us-gaap	Accrued Liabilities Fair Value Disclosure AccruedLiabilitiesFairValueDisclosure	184100	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	428700	usd
CY2022Q4	adil	Future Cash FutureCash	1.2	usd
CY2022	adil	Common Stock Exercise Price CommonStockExercisePrice	150000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Beat Amount EffectiveIncomeTaxRateReconciliationBeatAmount	4000000	usd
CY2022	us-gaap	Other Restrictions On Payment Of Dividends OtherRestrictionsOnPaymentOfDividends	$11
CY2022	adil	Cash Payment Of Aggregate Amount CashPaymentOfAggregateAmount	50000000	usd
CY2022	adil	Aggregate Purchase Price AggregatePurchasePrice	750000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	550000	usd
CY2022	adil	Aggregate Shares AggregateShares	1829269	shares
CY2022	adil	Percentage Of Common Stock PercentageOfCommonStock	0.10	pure
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.41
CY2022	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	134969	eur
CY2022	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	143685	usd
CY2022	us-gaap	Debt Instrument Fee DebtInstrumentFee	$22,000
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent		usd
CY2022	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt		usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	adil	Reclassification Of Stockbased Comp From Accrued Expenses ReclassificationOfStockbasedCompFromAccruedExpenses		usd
CY2022	adil	Noncash Cost Of Commitment Shares NoncashCostOfCommitmentShares		usd
CY2021	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation		shares
CY2022Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Opening Balance Adjustments LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseOpeningBalanceAdjustments		usd
CY2021	us-gaap	Business Acquisition Pro Forma Earnings Per Share Diluted BusinessAcquisitionProFormaEarningsPerShareDiluted	-1.05
CY2020Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment		usd
CY2021Q4	adil	Manufacturing Expenses ManufacturingExpenses		usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Restricted Stock Expense RestrictedStockExpense		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts		usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2022	adil	Supplemental Noncash Amounts Of Lease Liabilities Arising From Obtaining Right Of Use Assets SupplementalNoncashAmountsOfLeaseLiabilitiesArisingFromObtainingRightOfUseAssets		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001513525

Files In Submission

Name	View Source	Status
0001213900-23-024719-index-headers.html	Edgar Link	pending
0001213900-23-024719-index.html	Edgar Link	pending
0001213900-23-024719.txt	Edgar Link	pending
0001213900-23-024719-xbrl.zip	Edgar Link	pending
adil-20221231.xsd	Edgar Link	pending
f10k2022ex21-1_adialpharma.htm	Edgar Link	pending
f10k2022ex23-1_adialpharma.htm	Edgar Link	pending
f10k2022ex23-2_adialpharma.htm	Edgar Link	pending
f10k2022ex31-1_adialpharma.htm	Edgar Link	pending
f10k2022ex31-2_adialpharma.htm	Edgar Link	pending
f10k2022ex32-1_adialpharma.htm	Edgar Link	pending
f10k2022ex32-2_adialpharma.htm	Edgar Link	pending
f10k2022_adialpharma.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
adil-20221231_def.xml	Edgar Link	unprocessable
adil-20221231_lab.xml	Edgar Link	unprocessable
adil-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_adialpharma_htm.xml	Edgar Link	completed
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
adil-20221231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil

2023 Q1 Form 10-K Financial Statement

#000121390023024719 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL ADIAL PHARMACEUTICALS, INC. Stock $adil

2023 Q1 Form 10-K Financial Statement

#000121390023024719 Filed on March 30, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ADIL
ADIAL PHARMACEUTICALS, INC. Stock $adil